Prevention and early treatment of opportunistic viral infections in patients with leukemia and allogeneic stem cell transplantation recipients.
A leading complication of leukemia therapy and stem cell transplantation is opportunistic viral infections. Infections caused by cytomegalovirus, herpes simplex, varicella-zoster, Epstein-Barr, and the community respiratory viruses are associated with significant morbidity and mortality in this highly immunosuppressed population. Fortunately, a growing armamentarium is allowing more effective prophylaxis of these pathogens. This article reviews the epidemiology and prophylactic strategies available for these common opportunistic viral pathogens.
Angarone
Michael
M
Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Ison
Michael G
MG
D000998:Antiviral Agents / Q000008:administration & dosage; D001562:Benzimidazoles / Q000008:administration & dosage; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000517:prevention & control; D017245:Foscarnet / Q000008:administration & dosage; D015774:Ganciclovir / Q000008:administration & dosage; D006562:Herpes Zoster / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D007106:Immune Sera / Q000008:administration & dosage; D007116:Immunization, Passive; D016867:Immunocompromised Host; D007938:Leukemia / Q000453:epidemiology / Q000601:surgery*; D009894:Opportunistic Infections / Q000188:drug therapy / Q000517:prevention & control*; D012263:Ribonucleosides / Q000008:administration & dosage; D033581:Stem Cell Transplantation; D014777:Virus Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control*; D004004:Dichlororibofuranosylbenzimidazole / Q000031:analogs & derivatives
D000998:Antiviral Agents; D001562:Benzimidazoles; D017245:Foscarnet; D015774:Ganciclovir; D007106:Immune Sera; D012263:Ribonucleosides; C030799:varicella-zoster immune globulin; C400401:maribavir; D004004:Dichlororibofuranosylbenzimidazole